Born in 1979 and educated cellular biologist. She received her PhD from Karolinska Institute (KI) in 2005, where her dissertation topic was Immune modulation by mesenchymal stem cells. Ida then worked at Uppsala University, researching both how stromal cells interact with blood and whether stromal cells can improve the transplantation of insulin producing cellular islets. In 2008 she joined the private pharmaceutical company TikoMed AB and worked primarily with pre-clinical development of the company’s product portfolio. Between 2017 and 2019, Ida worked for Katarina Le Blanc at KI on clinical development and production of MSC pharmaceutical products.
“Pharmaceutical product development requires completely different skills, driving forces, and financing than those presently available in academia. Cell therapy is the ultimate area for academic and industrial cooperation in order to satisfy the increasing need for individually-adapted pharmaceutical products as quickly as possible.”
Chief Medical Officer